This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

XOMA's Management Presents At Morgan Stanley Global Healthcare Conference (Transcript)

Our particular drug is the most potent of all those that are out there. And as a result of that it could be administered in a very small volume and we anticipate that will be less than 1 ml of fluid given once per month subcutaneously. It’s also quite stable which will allow us to ultimately have this available for self-administration. As far as I know it’s the only one that’s out there. And we have seen virtually no injection side reactions, which again, if you look at the label of the competitors, in no case are they devoid of injection side reactions. So that’s potentially another advantage.

So I think from it’s both physical and [chemical] characteristics and its potency and its ease of use, plus its mechanism, it’s clearly distinct from the other candidates or the drugs that are out there.

Yigal Nochomovitz - Morgan Stanley

You mentioned the lead indication and you are in non-infectious uveitis, you have also seen some solid data in related form of that disease called the Behçet's. Could you discuss a bit some of the data there and whether the mechanism that you have described for your gevokizumab is special for that disease or if other INLINE-1 antibodies could potentially show efficacy in that setting.

Paul Rubin

That’s a good question. First of all, uveitis is a syndrome, not unlike asthma, in which there are multiple (inaudible), Behçet's uveitis being one. So in fact Behçet's isn’t related, it is not infectious uveitis, it’s just one of the forms. In all cases, independent of the underlying [mediology], it presents clinically in the same way. So all cases they end of with inflammation of the uvea, which is kind of the middle lining around the eye. And as a result of that inflammation, they end up with the same clinical signs and symptoms. And in fact in the United States, the FDA doesn’t discern between Behçet's uveitis and other forms. It’s all non-infectious uveitis.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs